(3-Carboxypropyl) triphenyl phosphonium bromide (CTPP) (No. 349720), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine semisynthetic (DPPC) (No. P0763), 2-amino-ethanethiol hydrochloride, 4,4′-azobis(4-cyanovaleric acid) (ABCPA) (No. 11590), cholesterol (No. C3045), N,N′-dicyclohexylcarbodiimide (DCC) (No. D80002), hydrated p-toluenesulfonic acid (PTSA) (No. 402885), 2-aminoethanethiol hydrochloride (AET-HCl) (No.122920), N-hydroxysuccinimide (NHS) (No.130672), poly(ethylene glycol) methyl ether (mPEG; MW = 5000) (No. 81323), L-histidine (No. H6034), and thiazolyl blue tetrazolium bromide (MTT) (No. M5655) were purchased from Sigma-Aldrich. 1-Ethyl-3-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (EDC·HCl) (No. D1601) was purchased from TLC. 4-Dimethylaminopyride (DMAP) (No. A13016) was purchased from Alfa Aesar. Methacrylic acid (MAAc) (No. AC168310250) was purchased from ACROS. All organic solvents were purchased from Merck.
Shueng P.W., Yu L.Y., Hou H.H., Chiu H.C, & Lo C.L. (2022). Charge Conversion Polymer–Liposome Complexes to Overcome the Limitations of Cationic Liposomes in Mitochondrial-Targeting Drug Delivery. International Journal of Molecular Sciences, 23(6), 3080.
+ Open protocol